Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon.

ABSTRACT: Some therapies for diabetes increase the risk of hypoglycaemia, in particular all insulins and insulin secretagogues, including the glinides and sulfonylureas. Hypoglycaemia remains a major limiting factor to successful glycaemic management, despite the availability of prevention options such as insulin analogues, continuous glucose monitoring, insulin pumps, and dogs that have been trained to detect hypoglycaemia. Non-severe (self-treated) and severe (requiring assistance for recovery) hypoglycaemia rates are higher in people with type 1 diabetes, but those with insulin-treated type 2 diabetes are also at risk. Education and regular review are essential between people with diabetes and their caregivers and healthcare professionals about symptoms, prevention and treatment. Awareness of the

SUBMITTER: Thieu VT 

PROVIDER: S-EPMC7079012 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature